<DOC>
	<DOCNO>NCT01620528</DOCNO>
	<brief_summary>A randomize study evaluate safety efficacy elagolix management moderate severe endometriosis-associated pain adult premenopausal female subject .</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety Efficacy Elagolix Subjects With Moderate Severe Endometriosis-Associated Pain</brief_title>
	<detailed_description>This Phase 3 , multicenter , double-blind , placebo-controlled , randomize study ass safety efficacy two dos elagolix ( Dose 1 Dose 2 ) versus placebo premenopausal 18 49 year old woman moderate severe endometriosis-associated pain . Approximately 875 subject enrol study approximately 160 site . The study consist 4 period : 1 ) Washout Period ( applicable ) ; 2 ) Screening Period 100 day prior first dose ; 3 ) 6 month Treatment Period ; 4 ) Post treatment Follow-up Period 12 month ( applicable ) . An electronic diary dispense training provide record endometriosis-associated pain , uterine bleeding , analgesic medication use endometriosis-associated pain daily basis . Pregnancy test perform monthly throughout study . Subjects require use non-hormonal dual contraception study , counsel appropriate effective form birth control promote pregnancy prevention .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>1 . Premenopausal female , 18 49 year age , inclusive , time signing consent . 2 . Clinical diagnosis endometriosis ( laparoscopy laparotomy ) perform within 10 year entry Washout Period . 3 . Agrees use required birth control method entire length participation study . 4 . Subject Composite Pelvic Signs Symptoms Score total score â‰¥ 6 Screening score least 2 dysmenorrhea AND least 2 nonmenstrual pelvic pain . 5 . Subjects must least two menstrual cycle 24 38 day within Screening Period , prior Day 1 1 . Subject pregnant breast feed planning pregnancy within next 24 month le 6 month postpartum , postabortion , postpregnancy time entry Screening Period . 2 . Subject history previous nonresponse GnRH agonist , GnRH antagonists , Depot Medroxyprogesterone Acetate , aromatase inhibitor assess subject report improvement dysmenorrhea nonmenstrual pelvic pain ( subject report partial response side effect agent exclusionary ) . 3 . Subject chronic pelvic pain cause endometriosis require chronic analgesic chronic therapy , would interfere assessment endometriosis relate pain . 4 . Clinically significant gynecologic condition identify Screening transvaginal ultrasound endometrial biopsy . 5 . Subject history osteoporosis metabolic bone disease . 6 . Subject current history undiagnosed abnormal genital bleeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gonadotropin-Releasing Hormone Antagonist</keyword>
	<keyword>Endometriosis associate pain</keyword>
	<keyword>Dysmenorrhea ( DYS )</keyword>
	<keyword>Non-Menstrual Pelvic Pain ( NMPP )</keyword>
	<keyword>Elagolix</keyword>
</DOC>